Objective: To explore the role of long intergenic non-coding ribonucleic acid 483 (LINC00483) in the development of breast cancer (BC) and its possible mechanism of action.
Patients and methods: LINC00483 expression level in BC tissues and cell lines was detected via quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). The association between LINC00483 expression and survival rate of BC patients was analyzed using Kaplan-Meier survival analysis. The binding relation between LINC00483 and insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) was verified via RNA immunoprecipitation (RIP) and RNA pull-down assays. The expression of IGF2BP1 in BC patients was determined using qRT-PCR. Moreover, the role of LINC00483 on the proliferative ability of BC cells was detected via cell counting kit-8 (CCK8) and 5-Ethynyl-2'-deoxyuridine (EdU) assays. Whether LINC00483 exerts its effects under the regulation of IGF2BP1 was verified via reversal assay.
Results: The results of qRT-PCR showed that LINC00483 had a significantly high expression in BC tissues and corresponding cell lines, and it rose with the increase in tumor stage, which was higher in patients with metastasis. CCK8/EdU assay revealed that the proliferative ability of MDA-MB-231 and MCF-7 cell lines was enhanced by overexpression of LINC00483. It was confirmed by RIP and pull-down assays that IGF2BP1 could bind to LINC00483, and the expression of LINC00483 was significantly promoted after up-regulation of IGF2BP1. It was found via qRT-PCR that the expression of IGF2BP1 evidently rose in BC patients, which was positively related with the expression level of LINC00483. The results of reversal assay manifested that the function of LINC00483 on cell proliferation was regulated by IGF2BP1.
Conclusions: LINC00483 has a significantly higher expression in BC tissues than that in para-carcinoma tissues, and its effect of promoting proliferation of BC cells may be regulated by IGF2BP1.